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We congratulate the KDIGO (Kidney Disease: Improving Global Outcomes) work group on their compre-
hensive work in a broad subject area and agreed with many of the recommendations in their clinical practice
guideline on the evaluation and management of chronic kidney disease. We concur with the KDIGO definitions
and classification of kidney disease and welcome the addition of albuminuria categories at all levels of
glomerular filtration rate (GFR), the terminology of G categories rather than stages to describe level of GFR,
the division of former stage 3 into new G categories 3a and 3b, and the addition of the underlying diagnosis.
We agree with the use of the heat map to illustrate the relative contributions of low GFR and albuminuria to
cardiovascular and renal risk, though we thought that the highest risk category was too broad, including as it
does people at disparate levels of risk. We add an albuminuria category A4 for nephrotic-range proteinuria and
D and T categories for patients on dialysis or with a functioning renal transplant. We recommend target blood
pressure of 140/90 mm Hg regardless of diabetes or proteinuria, and against the combination of angiotensin
receptor blockers with angiotensin-converting enzyme inhibitors. We recommend against routine protein re-
striction. We concur on individualization of hemoglobin A1c targets. We do not agree with routine restriction of
sodium intake to ,2 g/d, instead suggesting reduction of sodium intake in those with high intake (.3.3 g/d).
We suggest screening for anemia only when GFR is ,30 mL/min/1.73 m2. We recognize the absence of
evidence on appropriate phosphate targets and methods of achieving them and do not agree with suggestions
in this area. In drug dosing, we agree with the recommendation of using absolute clearance (ie, milliliters per
minute), calculated from the patient’s estimated GFR (which is normalized to 1.73 m2) and the patient’s actual
anthropomorphic body surface area. We agree with referral to a nephrologist when GFR is ,30 mL/min/
1.73 m2 (and for many other scenarios), but suggest urine albumin-creatinine ratio . 60 mg/mmol or pro-
teinuria with protein excretion . 1 g/d as the referral threshold for proteinuria.
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Akbari et alMETHODS
The commentary committee co-chairs selected poten-
tial members from their knowledge of the Canadian
kidney community, aiming to represent people from
the whole range of relevant disciplines, from academic
and community centers, and from across Canada. Some
committee members were identiﬁed through snowball
methodology from other experts, and others were iden-
tiﬁed through internet searches of academic departments.
Once the commentary committee was determined,
we used the general methodology of other CSN
(Canadian Society of Nephrology) guidelines,2 and in
keeping with other commentaries, divided our com-
ments into those that we thought might interest
anyone in the international community of those who
care for people with CKD and those that were spe-
ciﬁcally directed at the Canadian context.
Each committee member ﬁrst provided comments on
the whole document, which were collated and circu-
lated. Though different people highlighted different
issues, there was general concordance at this stage.
Using this material, pairs of writers selected for their
expertise in the area wrote the ﬁrst draft of the com-
mentary and received feedback from a different pair and
from the co-chairs. Subsequent drafts received feedback
from all committee members. We used teleconferences
selectively to set up our plan of work and discuss
differences of opinion that arose during drafting. Our
process and decisions have been documented.
We considered our readership to be people like
ourselves: health care workers in primary, secondary,
or tertiary care who look after patients with kidney
disease, recognizing that some of the issues are
somewhat specialized and less relevant at the level of
primary care. We were explicitly primarily interested
in interventions that affect patient-important, rather
than surrogate, outcomes. We attempted to make our
recommendations clear and actionable. We accepted
that there were situations in which alternative courses
of action would be reasonable practice.
We attempted to produce suggestions and recom-
mendations that were in keeping with or at least recog-
nized the importance of our understanding of the values
and preferences of Canadians, along with addressing
resource and feasibility questions that are speciﬁcally
Canadian. Overall, our philosophy and processes have
been aligned with the suggestions of the Grading of
Recommendations Assessment, Development and
Evaluation (GRADE) working group.3
We noted that it was sometimes difﬁcult to un-
derstand the rationale for the level-of-evidence grad-
ings (see Item S1 [available as online supplementary
material] for examples); however, we recognized
that producing a consistent and evidence-based
recommendation for a large number of statements is178an enormous and difﬁcult task. We have not attemp-
ted to address this issue systematically. The material
we have quoted from the original KDIGO guideline
reproduces the original gradings, which we have not
modiﬁed and do not always agree with.
When we disagreed with the substance of the
KDIGO recommendation, we have indicated that and
discussed the reasons for our disagreement in the
commentary.
Screening. One important point that was beyond
the scope of the KDIGO CKD guideline, but which
often arose in our discussion, was the identiﬁcation of
people with CKD. Screening studies have shown very
large numbers needed to screen to identify a person
with progressive kidney disease.4 In the early stages
of disease, the evidence for differential intervention
(ie, using different treatments based on the knowledge
of the kidney disease) is not strong. Because of these
factors, along with the economic considerations and
the potential for adverse personal and insurance
consequences from labeling, we are not advocating
any form of screening at present. Practitioners
should continue to use case ﬁnding in keeping with
usual clinical practice: in people with new-onset or
long-standing hypertension or diabetes, people with
vascular disease, people who are to undergo major
surgery or be exposed to other potential causes of
acute kidney injury (AKI), people with multisystem
or generalized symptoms, people who are being
considered for nephrotoxic medications or medica-
tions that require dose adjustment for renal function,
people with a family history of polycystic kidney
disease or hereditary nephritis, and people from First
Nations populations or other ethnic groups known to
be at increased risk. In many of these cases, it is
glomerular ﬁltration rate (GFR) that is most relevant
and that may be the initial measurement. In people
with diabetes, urine albumin measurement is widely
used for case ﬁnding. Either initially or in people
identiﬁed with low GFR, it may be clinically appro-
priate to measure proteinuria, either as albumin-
creatinine ratio (ACR), protein-creatinine ratio
(PCR), or dipstick. We recognize that there is sub-
stantial within-individual day-to-day variation in
proteinuria, but do not think that it is appropriate to
recommend multiple measurements as an initial
approach (as tends to occur in people with diabetes).
Though multiple measurements inevitably have better
measurement properties than single measurements,
most of the evidence for the risk associated with low
GFR and proteinuria in general populations has been
based on single measurements,5-7 and routinely
implementing multiple measurements greatly in-
creases costs and complexity. In terms of follow-up
measurements, we recognize that even less is knownAm J Kidney Dis. 2015;65(2):177-205
Criteria for CKD (either of the following present for .3 months)
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
Reproduced with permission of KDIGO from1.
CSN Commentaryabout appropriate intervals for rescreening.8 For
people identiﬁed as having kidney disease,
remeasurement should be based on the severity of
the abnormality found, previous values, and the
clinical context. For those without kidney disease,
appropriate intervals for remeasurement might be
measured in years or, in some cases, decades.
We know that many agencies are working on
actionable algorithms for approach to the detection of
kidney disease in high-risk groups, guided by evidence,
opinion, and best practices and motivated by the desire
to prevent progression at early stages, when the impact
of reduction will be greatest. Studies of the impact of
these strategies will inform further recommendations
and, we hope, interventional studies in the area.
The structure of this commentary aligns with the
structure of the KDIGO guideline.1 Numbered text
within horizontal rules is quoted directly from the
KDIGO document, using the same numbering scheme
as in the original (all material is reproduced with
permission of KDIGO). The text that follows, written
by the commentary committee, comments on key
guideline recommendations and discusses special
implications for Canada.
DEFINITION AND CLASSIFICATION OF CKD
Deﬁnition of CKD1.1.1: CKD is defined as abnormalities of kidney structure or
function, present for .3 months, with implications
for health. (Not Graded) [see table titled “Criteria for
CKD (either of the following present for .3 months)”]GFR categorie
Abbreviations: CKD, chronic kidney disease; GFR, glomerular fil
*Relative to young adult level.
In the absence of evidence of kidney damage, neither GFR cate
Reproduced with permission of KDIGO from1.
Am J Kidney Dis. 2015;65(2):177-205Commentary
We agree that CKD should be deﬁned as the
presence of important kidney damage or decreased
kidney function for 3 or more months. A key criticism
of this conceptual deﬁnition in the literature is that the
parameters used in deﬁning CKD, such as asymp-
tomatic low GFR, albuminuria, and other asymp-
tomatic urinary abnormalities, are biomarkers, but not
disease entities.9 However, these biomarkers are
associated with increased risk of adverse clinical
outcomes (end-stage renal disease [ESRD], cardio-
vascular disease, and mortality) in community-
dwelling patients in the community and in
nephrology practices and should be considered within
their overall care.10,11 Some have recommended that
people in GFR category G3a without associated
markers of kidney damage (albuminuria or hematuria)
should not necessarily be considered to have CKD
and should be considered for further evaluation and
referral according to the clinical judgment of the
health care provider.9,12 Labeling people as having
CKD has important implications, including insurance
problems.13-15 We recommend that in patients with
estimated GFR (eGFR) , 60 mL/min/1.73 m2,
urine protein assessment (ACR, PCR, or a
dipstick) and a repeat measurement of kidney
function be undertaken. If the low GFR is likely
long term, the repeat assessment could be in 3
months, which would satisfy criteria for CKD.
However, if low GFR could be acute or subacute, the
repeat assessment should be made sooner, sometimes
within days, depending on the clinical situation, sos in CKD
tration rate.
gory G1 nor G2 fulfill the criteria for CKD.
179
Albuminuria categories in CKD
Abbreviations: AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease.
*Relative to young adult level.
**Including nephrotic syndrome (albumin excretion usually .2200 mg/24 hours [ACR . 2220 mg/g; .220 mg/mmol]).
Reproduced with permission of KDIGO from1.
Akbari et althat AKI can be recognized and further investigation
and treatment can proceed without delay.
Implications Within Canadian Health Care
The current operational deﬁnition for CKD is a useful
and pragmatic concept for practice, research, and policy
formulation. It provides a common language for
communication among health care providers, patients
and their families, investigators, and policy makers, at
the risk of labeling effects and insurability issues for
some Canadians. It has important implications for
public health and clinical practice as it provides a
framework for identifying patients at risk of adverse
outcomes (ESRD, cardiovascular risk, and mortality)
that does not always require specialist consultation.
Further, the framework also creates a potential for reli-
able estimates of the burden of CKD as hitherto,
nationwide data on CKD were available only for renal
replacement therapy (RRT) recorded through the Ca-
nadian Organ Replacement Registry.
Staging of CKD1.2.1: We recommend that CKD is classified based on
cause, GFR category, and albuminuria category
(CGA). (1B)
1.2.2: Assign cause of CKD based on presence or
absence of systemic disease and the location
within the kidney of observed or presumed pathologic-
anatomic findings. (Not Graded)
1.2.3: Assign GFR categories as follows (Not Graded)
[See table titled “GFR categories in CKD”]
1.2.4: Assign albuminuria* categories as follows (Not
Graded) [See table titled “Albuminuria categories
in CKD”]*note that where albuminuria measurement is not
available, urine reagent strip results can be substituted.
Commentary
The new classiﬁcation based on cause (C category),
GFR (G category), and albuminuria (A category) im-
proves construct validity (the ability of the classiﬁcation
to describe important aspects of CKD) at the expense of
greater complexity, a worthwhile tradeoff for nephrol-
ogists caring for patients as it is always possible
to collapse and simplify it as needed. We suggest that
an additional A4 category for nephrotic-range180proteinuria be added (albumin excretion rate
. 2,220 mg/d [ie, ACR. 2,220 mg/g or 220 mg/
mmol). This cut point is widely used in differential
diagnosis,withpatientswithnephrotic-range proteinuria
having a high likelihood of glomerular disease, and has
been long used in research to deﬁne particularly high-
risk groups for study. In the previous staging system,
CKD in patients on dialysis received subclassiﬁcation as
GFR stage 5D to highlight the specialized care that they
require, but this has nowbeen omitted and aggregated as
G5 (GFR, 15 mL/min/1.73 m2). Distinguishing pa-
tients on dialysis from those who are not is critical and
we recommend that the D designation continue to be
used; similarly, a T designation should continue to be
used for recipients of functioning kidney transplants.
Failure to make these distinctions risks extrapolation of
treatments and prognosis between patients with CKD
but not ESRDand those on dialysis andwith transplants.
Finally, the addition of cause to the classiﬁcation system
highlights the difﬁculties of managing CKD in primary
care (where most patients with CKD receive care):
clinical judgment is required to determine how likely the
problem is due to vascular disease, hypertension, or
diabetes; the leading causes; or whether further evalua-
tion for alternative, possibly treatable, diagnoses is
needed. Overall, this classiﬁcation, like the one it re-
places, is valuable to administration, clinicians, educa-
tors, and researchers in generating a standardized
stratiﬁcation.
Using Predicted Risk to Guide Testing and Treatment
Decisions1.3.1: In predicting risk for outcome of CKD, identify the
following variables: 1) cause of CKD; 2) GFR
category; 3) albuminuria category; 4) other risk factors
and comorbid conditions. (Not Graded)
1.3.2: In people with CKD, use estimated risk of concurrent
complications and future outcomes to guide
decisions for testing and treatment for CKD compli-
cations. (Not Graded)Commentary
With respect to recommendation 1.3.1, we discuss
risk prediction models in the commentary onAm J Kidney Dis. 2015;65(2):177-205
Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; Orange: high risk; Red, very high risk.
Reproduced with permission of KDIGO from1.
CSN Commentaryguideline recommendation 2.1.1. We concur with
recommendation 1.3.2.
Using a Heat Map to Understand the Association of
Low GFR and Proteinuria With Risk1.3.3: In populations with CKD, group GFR and
albuminuria categories with similar relative risk
for CKD outcomes into risk categories. (Not Graded)
[See figure titled “Prognosis of CKD by GFR
and Albuminuria Categories: KDIGO 2012”]Commentary
With the new guideline recommendations, patients
with CKD can now be risk stratiﬁed into 18 separate
categories based on GFR and albuminuria categories.
Outside decision support software, this is rather
complex for clinical application, especially in primary
care. The key message is that cardiovascular and renal
risk increase with lower GFR and higher albuminuria
or proteinuria, and that the increase in risk is at least
additive. The heat map is helpful in illustrating this.
We suppose that the choice of risk category bound-
aries (where the color changes) was informed by the
desire to facilitate primary care decision making;
however, because the classiﬁcation system will be
used in many other contexts, we did not concur that
the highest risk category should include such a
broad range of risk. Those within the red category
with highest proteinuria and lowest GFR carry risks
that are quantitatively different from those at the
borders and should be distinguished in the heat map.
Clinical judgment, guided by a few key principles,
will continue to determine who to refer.Am J Kidney Dis. 2015;65(2):177-205Evaluation of CKD Chronicity and Cause1.4.1: Evaluation of chronicity
1.4.1.1: In people with GFR, 60 ml/min/1.73 m2 (GFR
categories G3a-G5) or markers of kidney
damage, review past history and previous measure-
ments to determine duration of kidney disease.
(Not Graded) If duration is .3 months, CKD is confirmed.
Follow recommendations for CKD.
 If duration is not .3 months or unclear, CKD
is not confirmed. Patients may have CKD or
acute kidney diseases (including AKI) or both
and tests should be repeated accordingly.1.4.2: Evaluation of cause
1.4.2.1: Evaluate the clinical context, including personal
and family history, social and environmental factors,
medications, physical examination, laboratory
measures, imaging, and pathologic diagnosis to deter-
mine the causes of kidney disease. (Not Graded)Commentary
We concur with guideline recommendations
1.4.1.1 and 1.4.2.1.
Use of Serum Creatinine and Cystatin C in Estimating
GFR1.4.3.1: We recommend using serum creatinine and a GFR
estimating equation for initial assessment. (1A)
1.4.3.2: We suggest using additional tests (such as
cystatin C or a clearance measurement) for
confirmatory testing in specific circumstances when
eGFR based on serum creatinine is less
accurate. (2B)
1.4.3.3: We recommend that clinicians (1B): use a GFR estimating equation to derive
GFR from serum creatinine (eGFRcreat) rather181
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Akbari et althan relying on the serum creatinine concentra-
tion alone.
 understand clinical settings in which eGFRcreat is
less accurate.Commentary
We concur with recommendations 1.4.3.1 and
1.4.3.3. With respect to recommendation 1.4.3.2, a
number of low-molecular-weight serum proteins,
such as b2-microglobulin, retinol-binding protein, and
cystatin C, are proposed as suitable alternative
endogenous ﬁltration markers.16 Of these, cystatin C
has received the most interest in the published liter-
ature. Several studies have compared the accuracy of
serum cystatin C and creatinine in relation to a
reference standard of GFR,17-19 most ﬁnding the
measurement properties of serum cystatin C to be
similar to or better than those of serum creatinine.
However, some studies have potential weaknesses,
including lack of assay standardization, inadequate
sample sizes, selection of an inappropriate reference
standard for GFR, variable choice of GFR cutoff level
discriminating normal from impaired kidney function,
lack of standardization of GFR to body surface area,
and uncertain generalizability of data. In addition,
validated information on cystatin C performance
properties as a GFR surrogate in infants, children,
adolescents, and young adults with CKD is currently
lacking. However, the biggest issue is lack of evi-
dence of effectiveness (are outcomes improved by
more accurate risk stratiﬁcation?) and cost-effective-
ness.20 We do not recommend the widespread use
of cystatin C in clinical practice.
Implications Within Canadian Health Care
With respect to recommendation 1.4.3.2, although
cystatin C reference ranges have been reported, there
is no standard reference for calibration of measure-
ments across laboratories in Canada (work is in
progress) and availability is limited to reference lab-
oratories at present. We do not consider this prob-
lematic as its effectiveness has yet to be
demonstrated.
Reporting of eGFR1.4.3.4: We recommend that clinical laboratories should (1B): measure serum creatinine using a specific
assay with calibration traceable to the interna-
tional standard reference materials and minimal
bias compared to isotope-dilution mass
spectrometry (IDMS) reference methodology.
 report eGFRcreat in addition to the serum creati-
nine concentration in adults and specify the
equation used whenever reporting eGFRcreat.
 report eGFRcreat in adults using the 2009 CKD-
EPI creatinine equation. An alternative
creatinine-based GFR estimating equation
is acceptable if it has been shown to improveaccuracy of GFR estimates compared to the
2009 CKD-EPI creatinine equation.When reporting serum creatinine: We recommend that serum creatinine concen-
tration be reported and rounded to the nearest
whole number when expressed as standard
international units (mmol/l) and rounded to the
nearest 100th of a whole number when
expressed as conventional units (mg/dl).When reporting eGFRcreat: We recommend that eGFRcreat should be re-
ported and rounded to the nearest whole number
and relative to a body surface area of 1.73 m2
in adults using the units ml/min/1.73 m2.
 We recommend eGFRcreat levels less than 60 ml/
min/1.73 m2 should be reported as ‘‘decreased.’’Commentary
GFR is inﬂuenced by physiologic stressors such as
acute illness, vasodilation (eg, sunburns), hydration
status, vigorous activity, hormonal inﬂuences (pu-
berty, pregnancy, menopause, and andropause), and
medications. These caveats must be taken into ac-
count in interpreting reported eGFR. Furthermore,
inpatients may not be, and people with subacute or
acute kidney injury are not, in steady state. However,
reporting has raised awareness of CKD and has uses
in clinical practice and administration, as well as in
research.
Pediatric considerations. We suggest that in
younger children, measured GFR evaluations be
delayed at least 2 weeks after any intercurrent ill-
nesses (opinion). This is especially relevant when
GFR is being used to make the decision for pre-
emptive renal transplant listing.
Implications Within Canadian Health Care
No study has demonstrated improved patient-
important outcomes with routine laboratory report-
ing of eGFR.21,22 Implementation of eGFR has been
widely studied in Canada and been found to be
associated with a 2% increase in prescription of renin-
angiotensin system (RAS) blockade to people with
low GFRs23; no reduction in inappropriate dosing of
antibiotics in people with CKD24; an increase in re-
ferrals,25,26 workload,26 and waiting times to see a
nephrologist26; an increase in the number of referrals
of people with eGFRs , 30 mL/min/1.73 m2 in one
study25 and no change in another26; an increase in the
total number of appropriate referrals, but no change in
the proportion of appropriate referrals25; an increase
in the proportion of women and elderly people
referred25; and no change in eGFR at initiation of
dialysis.27 In Australia, the proportion of late referrals
decreased slightly (from 24% to 20%) with the initi-
ation of eGFR reporting: there were more marked
effects for First Nations peoples and a decrease in late
referral for older patients, but an increase in lateAm J Kidney Dis. 2015;65(2):177-205
CSN Commentaryreferral for younger patients.28 Rightly or wrongly,
routine eGFR reporting is a fait accompli, and we
acknowledge this by using eGFR throughout in our
recommendations.
Calibration of serum creatinine to the gold stan-
dard of isotope-dilution mass spectrometry is an
essential prerequisite to the use of any formula to
estimate GFR.29,30 To estimate GFR, either the
MDRD (Modiﬁcation of Diet in Renal Disease)
Study equation31 or the CKD-EPI (CKD Epidemi-
ology Collaboration) equation32 may be used. We
recommend the use of the latter because of its better
accuracy, particularly at high GFRs32-34; validity
(ability to discriminate between individuals at
different risks)35-37; and calibration (ability to
accurately predict the magnitude of risk).35-37 There
is little difference in ease of implementation: both
require the input of a variable for ethnicity (black
vs nonblack) that is not usually available at a lab-
oratory level, but that can be incorporated by
treating physicians during interpretation. Either can
be used in patients with transplants.38 Though these
are the most accurate methods available to clinical
practice and represent improvements over measured
creatinine clearance by 24-hour collection, knowing
that their accuracy is limited (in 16%-20% of
people with eGFR , 60 mL/min/1.73 m2, the true
value differs from the reported estimate by
.30% of the reported estimate17,32) is critical to
understanding the meaning of estimates and opti-
mizing the use of estimating equations in clinical
practice.
Use of Cystatin C and Measured GFR1.4.3.5: We suggest measuring cystatin C in adults with
eGFRcreat 45–59 ml/min/1.73 m
2 who do not have
markers of kidney damage if confirmation of CKD
is required. (2C)Am J Kidn If eGFRcys/eGFRcreat-cys is also ,60 ml/min/
1.73 m2, the diagnosis of CKD is confirmed.
 If eGFRcys/eGFRcreat-cys is $60 ml/min/1.73 m2,
the diagnosis of CKD is not confirmed.1.4.3.6: If cystatin C is measured, we suggest that health
professionals (2C): use a GFR estimating equation to derive GFR
from serum cystatin C rather than relying on
the serum cystatin C concentration alone.
 understand clinical settings in which eGFRcys
and eGFRcreat-cys are less accurate.1.4.3.7: We recommend that clinical laboratories that mea-
sure cystatin C should (1B): measure serum cystatin C using an assay with
calibration traceable to the international standard
reference material.
 report eGFR from serum cystatin C in addition to
the serum cystatin C concentration in adults
and specify the equation used whenever report-
ing eGFRcys and eGFRcreat-cys.
 report eGFRcys and eGFRcreat-cys in adults using
the 2012 CKD-EPI cystatin C and 2012 CKD-EPIey Dis. 2015;65(2):177-205creatinine-cystatin C equations, respectively,
or alternative cystatin C-based GFR estimating
equations if they have been shown to improve
accuracy of GFR estimates compared to
the 2012 CKD-EPI cystatin C and 2012 CKD-EPI
creatinine-cystatin C equations.When reporting serum cystatin C: We recommend reporting serum cystatin C con-
centration rounded to the nearest 100th of
a whole number when expressed as conven-
tional units (mg/l).When reporting eGFRcys and eGFRcreat-cys: We recommend that eGFRcys and eGFRcreat-cys
be reported and rounded to the nearest whole
number and relative to a body surface area
of 1.73 m2 in adults using the units ml/min/
1.73 m2.
 We recommend eGFRcys and eGFRcreat-cys
levels less than 60 ml/min/1.73 m2 should be
reported as ‘‘decreased.’’1.4.3.8: We suggest measuring GFR using an exogenous
filtration marker under circumstances where more
accurate ascertainment of GFR will impact on
treatment decisions. (2B)Commentary
We disagree that measuring cystatin C has a place
in routine clinical practice (recommendations 1.4.3.5
through 1.4.3.7; see the comments on guideline
statement 1.4.3.2). We concur with recommendation
1.4.3.8.
Evaluation of Albuminuria1.4.4.1: We suggest using the following measurements for
initial testing of proteinuria (in descending order
of preference, in all cases an early morning urine
sample is preferred) (2B);1) urine albumin-to-creatinine ratio (ACR);
2) urine protein-to-creatinine ratio (PCR);
3) reagent strip urinalysis for total protein with
automated reading;
4) reagent strip urinalysis for total protein with
manual reading.1.4.4.2: We recommend that clinical laboratories report ACR
and PCR in untimed urine samples in addition
to albumin concentration or proteinuria concentra-
tions rather than concentrations alone. (1B)
1.4.4.2.1: The term microalbuminuria should no longer be
used by laboratories. (Not Graded)
1.4.4.3: Clinicians need to understand settings that may
affect interpretation of measurements of albumin-
uria and order confirmatory tests as indicated
(Not Graded): Confirm reagent strip positive albuminuria
and proteinuria by quantitative laboratory
measurement and express as a ratio to creat-
inine wherever possible.
 Confirm ACR$ 30 mg/g ($3 mg/mmol) on a
random untimed urine with a subsequent early
morning urine sample.
 If a more accurate estimate of albuminuria
or total proteinuria is required, measure albu-
min excretion rate or total protein excretion rate
in a timed urine sample.183
Akbari et al1.4.4.4: If significant non-albumin proteinuria is suspected,
use assays for specific urine proteins (e.g., a1-
microglobulin, monoclonal heavy or light chains,
[known in some countries as ‘‘Bence Jones’’
proteins]). (Not Graded)Commentary
Urine protein excretion has important prognostic
implications not only for CKD progression, but also
for risk of other adverse clinical outcomes, including
all-cause mortality and cardiovascular events, irre-
spective of baseline kidney function.10,11 The
KDIGO CKD guideline recommends using ACR,
with suggestions for alternative measures based on
available resources for different settings across the
world. In CKD other than diabetic nephropathy,
proteinuria may be a better marker of glomerular
damage and risk of CKD progression, particularly in
the range of protein excretion . 1 g/d. Most previ-
ous research in renal populations has used protein-
uria as a measure of risk. The choice of ACR over
PCR and the other semiquantitative measures was
not based on their relative abilities to quantify urine
protein excretion, but a better precision of ACR
measurements particularly at lower levels of protein
excretion in the urine.39 The value of repeat,
conﬁrmatory, and complementary measurements of
proteinuria (recommendation 1.4.4.3) has not been
shown. If a monoclonal gammopathy is suspected
(1.4.4.4), serum and urine protein electrophoresis
should be performed.
Implications Within Canadian Health Care
For assessment of urine protein, we are con-
cerned that exclusive application of the ACR measure
across the country may have signiﬁcant resource im-
plications considering the differential cost of the
various tests (eg, in Alberta, direct costs are $0.50 for
reagent strip, $1.00 for PCR, and $2.00 for ACR; G.
Cembrowski, MD, PhD [Director, Medical
Biochemistry, University of Alberta Hospital], per-
sonal communication, September 2014), though this
will vary by region and change over time. However,
we recognize the need to develop local clinically
sensible algorithms for risk stratiﬁcation and diag-
nosis that incorporate a standardized approach, in
which case, though each of the 3 measures has dis-
advantages, we consider each of them appropriate.
DEFINITION, IDENTIFICATION, AND PREDICTION
OF CKD PROGRESSION
Recognition of CKD in Canada occurs through
case ﬁnding, as the evidence for screening is not
strong and is not recommended as part of our periodic
health examination.40 The difference in rates of pro-
gression of kidney diseases for patients in primary184care and those seen by nephrologists is a testament to
appropriate referral and retention patterns by both sets
of practitioners. The recognition and referral to ne-
phrologists of unusual, unexplained, progressive, or
severe manifestations of kidney disease is a complex
task requiring knowledge and experience, which this
KDIGO guideline and our commentary will supple-
ment rather than replace.
Frequency of eGFR and Albuminuria Measurements2.1.1: Assess GFR and albuminuria at least annually in
people with CKD. Assess GFR and albuminuria more
often for individuals at higher risk of progression, and/
or where measurement will impact therapeutic de-
cisions. (Not Graded)Commentary
Most people with low GFRs are followed up in
primary care or by other specialists rather than ne-
phrologists.41 In unselected nondiabetic people with
low GFRs who are not followed up in nephrology
practices, the average rate of change of kidney func-
tion is 0.05 to 1.5 mL/min per year,41,42 which does
not differ greatly from expected age-related decline.43
People with diabetes and African Americans
with hypertension experience rates of loss of 2.0 to
2.7 mL/min per year.44,45 However, patients referred
to nephrologists experience rates of decline of 2.7 to
4.9 mL/min per year.46-48 There is no evidence that
frequent monitoring of low GFR and albuminuria
in the community improves outcomes, and it is
difﬁcult to translate the slow average rates of pro-
gression into a prescription for frequency of moni-
toring. Furthermore, though decreases in albuminuria
predict better outcomes, there is no randomized evi-
dence that targeting a lower albuminuria level im-
proves clinical outcomes.
The risk stratiﬁcation heat map is difﬁcult to
memorize: we offer the alternative suggestion that
for people with CKD but without diabetes, eGFR
be determined when there is an important change
in health status and when considering prescribing
a medication affected by eGFR, and that albu-
minuria be assessed initially and reassessed to
assess the etiology of new edema and whenever
knowledge of albuminuria will affect management,
such as prescribing RAS blockade. After the ﬁrst 2
eGFR values have established the diagnosis of CKD
and provided initial information about trajectory, we
suggest routinely reassessing eGFR at clinically
relevant intervals, more often the lower the eGFR,
the more rapid the decrease in eGFR, and the
higher the albuminuria at baseline. This suggestion
is provided as an addition to usual clinical care
and monitoring and not as a substitute for clinical
judgment.Am J Kidney Dis. 2015;65(2):177-205
CSN CommentaryDeﬁnition of CKD Progression2.1.2: Recognize that small fluctuations in GFR are common
and are not necessarily indicative of progression.
(Not Graded)
2.1.3: Define CKD progression based on one of more of the
following (Not Graded):Am J Ki Decline in GFR category ($90 [G1], 60–89 [G2],
45–59 [G3a], 30–44 [G3b], 15–29 [G4], ,15
[G5] ml/min/1.73 m2). A certain drop in eGFR
is defined as a drop in GFR category accompanied
by a 25% or greater drop in eGFR from baseline.
 Rapid progression is defined as a sustained
decline in eGFR of more than 5 ml/min/1.73 m2/yr.
 The confidence in assessing progression is
increased with increasing number of serum creat-
inine measurements and duration of follow-up.2.1.4: In people with CKD progression, as defined in
Recommendation 2.1.3, review current manage-
ment, examine for reversible causes of progres-
sion, and consider referral to a specialist.
(Not Graded)Commentary
We concur with recommendations 2.1.2 and 2.1.4.
With respect to statement 2.1.3, we did not under-
stand the rationale for including change between
categories in the deﬁnition of progression given the
arbitrary nature of category boundaries: we thought
that a change, for example, in GFR from 80 to
60 mL/min/1.73 m2 should have the same signiﬁ-
cance (in practice and research) as 75 to 56 mL/min/
1.73 m2, though one crosses a boundary and the
other does not; however, we recognized the work
validating the deﬁnition.49,50 We also note that by
this deﬁnition, progression was not a signiﬁcant
predictor of ESRD when adjusted for most recent
eGFR. Further work on the prognostic implications
of changes in eGFR is needed. Rapid progression,
deﬁned as loss of eGFR . 5 mL/min/1.73 m2 per
year, predicts vascular events, death, and
ESRD,1(p68),51-55 which adds to our idea that it is a
valid measure (ie, improves its construct validity).
Additional GFR estimates increase the accuracy of
the determination of rapid progression. The timing of
routine interval re-evaluations for progression
should be determined by the eGFR (the lower, the
sooner), the rapidity of progression based on avail-
able values, and the clinical context. Health care
practitioners should also remain sensitive to the
possibility that a change in eGFR reﬂects an AKI
that mandates prompt re-evaluation.
Pediatric considerations. The trend of GFR as-
sessments over time is more relevant than a particular
speciﬁc assessment. Children are in a unique position
for expected growth and development inclusive of
capacity for renal growth, maturation of renal func-
tion, and recovery from renal insult. In addition,
children tend to have less nephrotoxic burden due todney Dis. 2015;65(2):177-205lower prevalence of chronic disease states compared
with adults. Somatic growth of the child is the
primary goal of pediatric care, which challenges
renal growth and functional capacity to adapt to
increased body demands. We endorse periodic GFR
assessments (corrected for body surface area) corre-
lated with somatic growth goals to evaluate progres-
sion and need for RRT.
Other Factors That Predict Progression of CKD2.2.1: Identify factors associated with CKD progression
to inform prognosis. These include cause of
CKD, level of GFR, level of albuminuria, age,
sex, race/ethnicity, elevated BP, hyperglycemia,
dyslipidemia, smoking, obesity, history of
cardiovascular disease, ongoing exposure to
nephrotoxic agents, and others. (Not Graded)Commentary
In addition to the evidence-based risk factors lis-
ted in the guideline, a 2013 systematic review56
identiﬁed 2 risk-prediction models for patients with
CKD that have acceptable measurement properties
and are usable at the point of care for the prediction
of ESRD.57,58 The ﬁrst is a points-based pen and
paper tool, which incorporates age, sex, eGFR, dia-
betes, hypertension, and hemoglobin to give a 5-year
risk of ESRD. The C statistic was 0.89, generally
regarded as excellent discrimination.57 This was
derived in a primary care data set and has not been
externally validated. The second, now known as the
kidney function risk equation, is an externally vali-
dated online or smartphone calculator59 that uses
age, sex, eGFR, urine ACR, albumin, phosphate,
bicarbonate, and calcium to predict 2- and 5-year
risk. These risk equations may be useful to further
inform prognosis. However, whether use of these
tools improves decisions about timing of specialist
referral or interventions is not yet known.
MANAGEMENT OF PROGRESSION AND
COMPLICATIONS OF CKD
Individualizing Blood Pressure Targets and
Treatments3.1.1: Individualize BP targets and agents according to age,
coexistent cardiovascular disease and other comor-
bidities, risk of progression of CKD, presence
or absence of retinopathy (in CKD patients with dia-
betes), and tolerance of treatment as described in the
KDIGO 2012 Blood Pressure Guideline. (Not Graded)
3.1.2: Inquire about postural dizziness and check for
postural hypotension regularly when treating CKD
patients with BP-lowering drugs. (Not Graded)
3.1.3: Tailor BP treatment regimens in elderly patients with
CKD by carefully considering age, comorbidities
and other therapies, with gradual escalation of treat-
ment and close attention to adverse events related to
BP treatment, including electrolyte185
Akbari et aldisorders, acute deterioration in kidney function,
orthostatic hypotension and drug side effects.
(Not Graded)Commentary
We concur with recommendations 3.1.1 through
3.1.3.
Blood Pressure Target in Hypertensive Patients With
CKD3.1.4: We recommend that in both diabetic and non-diabetic
adults with CKD and urine albumin excretion
,30 mg/24 hours (or equivalent) whose office BP
is consistently .140 mm Hg systolic or .90 mm Hg
diastolic be treated with BP-lowering drugs to
maintain a BP that is consistently #140 mm
Hg systolic and #90 mm Hg diastolic. (1B)
3.1.5: We suggest that in both diabetic and non-diabetic
adults with CKD and with urine albumin excretion
of$30 mg/24 hours (or equivalent) whose office BP is
consistently .130 mm Hg systolic or .80 mm
Hg diastolic be treated with BP-lowering drugs to
maintain a BP that is consistently #130 mm Hg
systolic and #80 mm Hg diastolic. (2D)Commentary
Though observational data consistently show that
lower achieved blood pressures (BPs) are associ-
ated with better outcomes than higher BPs, the
randomized evidence for further BP reduction to
targets less than 140/90 mm Hg has signiﬁcant
limitations.
Data for patients without diabetes are derived
from the long-term follow-up of the MDRD Study
and AASK (African American Study of Kidney
Disease) and from the REIN-2 (Ramipril Efﬁcacy in
Nephropathy 2) Study.60-62 None of the studies
observed a clinically important statistically signiﬁ-
cant difference in cardiovascular outcomes. In terms
of renal outcomes, a 2011 meta-analysis63 noted
that there was inconsistent evidence of beneﬁt in
both main effects and subgroup analysis of patients
with proteinuria; furthermore, the REIN-2 Study,61
conducted entirely in patients with proteinuria, did
not show beneﬁt. This last study has been criticized
for not having achieved wide group separation in
achieved BP. A 2013 meta-analysis64 (published
since the appearance of the KDIGO guideline)
observed a hazard ratio (HR) for ESRD of 0.79
(95% conﬁdence interval [CI], 0.67-0.93) overall,
1.12 (95% CI, 0.67-1.87) in a highly heterogeneous
analysis of patients without proteinuria, and 0.73
(95% CI, 0.62-0.86) in an analysis of patients with
proteinuria (with low heterogeneity). We do not
judge this ﬁnding robust because the absolute dif-
ference between groups in ESRD outcomes was just
9 events.186For people with diabetes and CKD, the evidence of
kidney protection from a lower BP target derives from
a single study of patients with A2 albuminuria and a
mean age of 55 years65 and is confounded by the
multiple cointerventions that were compared with
usual care. However, in a broader group of patients
with diabetes (but not CKD), ESRD was reported as
an adverse outcome in the ACCORD (Action to
Control Cardiovascular Risk in Diabetes) Study
(systolic BP , 120 vs 140 mm Hg) and was equiva-
lent in both groups (relative risk [RR], 1.01; 95% CI,
0.84-1.21).66 Cardiovascular outcomes, summarized
in a 2012 meta-analysis,67 were equivalent for mor-
tality (RR, 0.76; 95% CI, 0.55-1.05) and myocardial
infarction (RR, 0.93; 95% CI, 0.80-1.08), but risk for
stroke was lower (RR, 0.65; 95% CI, 0.48-0.86), this
last largely driven by the ﬁndings of the ACCORD
Study.
In conclusion, we recommend that in patients
without proteinuria who do not have diabetes,
standard targets (140/90 mm Hg) should be used.
We assessed the evidence for a lower BP target in
patients with proteinuria who do not have diabetes
and for a lower BP target in patients with diabetes,
regardless of proteinuria, as insufﬁcient to recom-
mend or suggest a lower target. We recognized the
limitations in the evidence and the interpretations of
other experts, including the CSN commentary on BP
management,68 by concluding that either standard or
lower target is reasonable in these patients.Implications Within Canadian Health Care
Patients with CKD G1 to G3 and many with G4
are commonly managed in primary care in Canada.
A uniform BP target reduces the need for repeat risk
stratiﬁcation and simpliﬁes treatment goals and
practice audit. Not seeking a lower BP target will
reduce by 0.5 to 1.0 the number of medications
needed,66 which is particularly relevant for those
who pay for medications out of pocket. Because
targeting lower BP is resource intensive and
associated with an increase in adverse events, we
advise against its implementation in policy and
quality initiatives.
Use of Angiotensin-Converting Enzyme Inhibitors and
Angiotensin Receptor Blockers3.1.6: We suggest that an ARB or ACE-I be used in diabetic
adults with CKD and urine albumin excretion 30–
300 mg/24 hours (or equivalent). (2D)
3.1.7: We recommend that an ARB or ACE-I be used in both
diabetic and non-diabetic adults with CKD and urine al-
bumin excretion.300 mg/24 hours (or equivalent). (1B)
3.1.8: There is insufficient evidence to recommend
combining an ACE-I with ARBs to prevent progression
of CKD. (Not Graded)Am J Kidney Dis. 2015;65(2):177-205
CSN Commentary3.1.9: We recommend that in children with CKD, BP-
lowering treatment is started when BP is consistently
above the 90th percentile for age, sex, and height.
(1C)
3.1.10: We suggest that in children with CKD (particularly
those with proteinuria), BP is lowered to consistently
achieve systolic and diastolic readings less than
or equal to the 50th percentile for age, sex, and
height, unless achieving these targets is limited
by signs or symptoms of hypotension. (2D)
3.1.11: We suggest that an ARB or ACE-I be used in chil-
dren with CKD in whom treatment with BP-lowering
drugs is indicated, irrespective of the level of
proteinuria. (2D)Commentary
We concur with recommendations 3.1.6 to 3.1.7.
We thought that recommendation 3.1.8 did not go far
enough: ONTARGET (Ongoing Telmisartan Alone
and in Combination With Ramipril Global Endpoint
Trial), which was a randomized trial conducted in
people with and without CKD who were at high
vascular risk, showed that the combination of full-
dose angiotensin-converting enzyme (ACE) in-
hibitors and full-dose angiotensin receptor blockers
(ARBs) increased the risk of hyperkalemia and AKI
without reducing cardiovascular outcomes, renal
outcomes, or death.69,70 Subgroup analysis showed no
beneﬁt in any CKD subgroup, though combined
blockade lowered proteinuria more than single agents
in this study, as in others. The VA NEPHRON-D
(Veterans Affairs Nephropathy in Diabetes) Study,
conducted in people with diabetes, GFR of 30 to
90 mL/min/1.73 m2, and urine ACR . 30 mg/mmol
(published since the KDIGO guideline was written),
also showed increased harm (AKI and hyperkalemia)
from combination treatment.71 We recommend that
the combination of ACE inhibitors and ARBs not
be routinely used.
With respect to the recommendations concerning
treatment of children (3.1.10-3.1.11), we agree with
the recommendation of the intervention used in the
ESCAPE (The Effect of Strict Blood Pressure Control
and ACE Inhibition on the Progression of CRF in
Pediatric Patients) trial,72 target mean arterial
pressure below the 50th percentile for age, based
on the reduction (HR, 0.65; 95% CI, 0.44-0.94) in the
outcome loss of 50% of GFR or ESRD in this ran-
domized study of (mostly proteinuric) children with
CKD.
Implications Within Canadian Health Care
We recommend not using ACE inhibitors with
ARBs in primary care. Specialists should recognize
that evidence that the combination alters clini-
cally important outcomes is lacking, even in heavily
proteinuric patients, and that adverse effects are
increased.Am J Kidney Dis. 2015;65(2):177-205CKD and Risk of AKI3.1.12: We recommend that all people with CKD are
considered to be at increased risk of AKI. (1A)
3.1.12.1: In people with CKD, the recommendations detailed
in the KDIGO AKI Guideline should be followed
for management of those at risk of AKI during
intercurrent illness, or when undergoing investi-
gation and procedures that are likely to increase
the risk of AKI. (Not Graded)Commentary
See the CSN commentary on the KDIGO AKI
guideline.73
Protein Intake3.1.13: We suggest lowering protein intake to 0.8 g/kg/day
in adults with diabetes (2C) or without diabetes
(2B) and GFR, 30 ml/min/1.73 m2 (GFR categories
G4-G5), with appropriate education.Commentary
The beneﬁcial effect of protein restriction, if
any, is probably modest, and there are clinically
important risks. Several well-designed randomized
controlled trials have evaluated the efﬁcacy of protein
restriction in patients with progressive CKD. In pa-
tients with diabetes, a Cochrane review published in
200774 found that protein restriction to approximately
0.6 to 0.8 g/kg per day was associated with a
nonsigniﬁcant reduction in the decline of GFR of
0.14 mL/min per month (95% CI, 20.06 to 0.34;
P 5 0.18; 7 studies).
In people without diabetes, a 2009 Cochrane re-
view showed a signiﬁcant overall decrease in ESRD
or death associated with a low-protein diet.75 How-
ever, studies that used moderate protein restriction
(deﬁned as 0.6 g/kg per day; 3 studies, 121 outcomes)
showed no signiﬁcant beneﬁt, whereas studies that
used a more stringent protein restriction of 0.3 to
0.6 g/kg per day showed beneﬁt (RR for ESRD or
death, 0.63; 95% CI, 0.48 to 0.83; P 5 0.0009; 7
studies, 160 outcomes). It is possible that protein re-
striction to 0.3 to 0.6 g/kg per day reduces renal
progression, but that less severe restriction does not.
Important long-term safety risks are associated with
low- and very low-protein diets in patients with
advanced CKD. Nutritional studies in patients with
CKD suggest that protein intake can be safely low-
ered to 0.6 g/kg per day providing caloric goals are
met, dietary protein is of high biological value, and
metabolic acidosis is avoided.76-79 However, a very
low-protein diet has been associated with increased
mortality: in the long-term follow-up of the MDRD
Study,80 assignment to a very low-protein diet (0.3 g/
kg per day) was associated with an increased risk of
death (HR, 1.92; 95% CI, 1.15-3.20).187
Akbari et alA number of factors make the interpretation of
study results on protein restriction difﬁcult. Vari-
ability in CKD stages, degree of proteinuria, type of
dietary protein provided, patient adherence to diet,
physician enthusiasm, BP control, and glycemic
control may have affected the outcomes of the various
published studies. Many of the studies on dietary
intervention were published before the widespread
use of RAS blockade.81 Because the proposed
mechanisms of action of RAS blockade and protein
restriction are similar (both reduce single-nephron
GFR),82,83 it is questionable whether any effect of
protein restriction would be additive to the effect of
RAS blockade. Because of the role of dietary proteins
on both renal hemodynamics and the accumulation of
metabolic toxins, evaluation of the true impact of
protein restriction is complex. For instance, protein
restriction may delay the initiation of dialysis therapy
by reducing the production of uremic toxins, thereby
reducing serum urea levels and clinical manifestations
of uremia, which are both factors in the decision to
start dialysis therapy, while having limited impact on
CKD progression per se.
The available evidence does not support, and we
do not recommend, routine protein restriction
(,0.8 g/kg per day) in patients with CKD. Protein
restriction may be reasonable for some patients if
certain conditions are all met: a well-nourished patient
who understands the risks and beneﬁts and the un-
certainty about them, who wishes and has the re-
sources to comply with dietary prescription, and who
has access to expert ongoing dietary supervision and
nutritional assessment, preferably by a dietitian.
Avoiding High Protein Intake3.1.14: We suggest avoiding high protein intake (.1.3 g/kg/
day) in adults with CKD at risk of progression. (2C)Commentary
Observational data suggest that a high total protein
intake, particularly high intake of nondairy animal
protein, may accelerate renal function decline in
people with CKD.84-86 No randomized controlled
trials have been performed, so strong recommenda-
tions cannot be made. However, there are no known
health risks to following diets that are lower in meat
and higher in vegetables (such as the Mediterranean
and DASH [Dietary Approaches to Stop Hyperten-
sion] diets). These diets lead to reductions in cardio-
vascular events in the general population.87,88 Eating
a diet rich in vegetables and fruit and a high score on
the Modiﬁed Alternate Healthy Eating Index
(mAHEI) are associated with lower risk of incident
CKD or progression of CKD in people with diabetes
and high vascular disease risk, as is moderate alcohol
intake.89188Pediatric considerations. Protein restriction should
not be undertaken in children with CKD because of
limited data on efﬁcacy and the concern that growth
90may be affected. In a meta-analysis published
in 2007, no signiﬁcant differences were found in
number of renal deaths (RR, 1.12; 95% CI, 0.54-
2.33), progression of kidney disease (mean difference
in creatinine clearance at 2 years, 1.47; 95%
CI, 21.19 to 4.14), or growth (mean difference in
weight, 20.13; 95% CI, 21.10 to 0.84; mean dif-
ference in height, 21.99; 95% CI, 24.84 to 0.86).
However, some concerns remained regarding adverse
effect on growth as some anthropometry data sug-
gested lower growth velocity with protein
restriction.90
Glycemic Control and Hemoglobin A1c Targets3.1.15: We recommend a target hemoglobin A1c (HbA1c) of
w7.0% (53 mmol/mol) to prevent or delay progres-
sion of the microvascular complications of diabetes,
including diabetic kidney disease. (1A)
3.1.16: We recommend not treating to an HbA1c target
of ,7.0% (,53 mmol/mol) in patients at risk of hy-
poglycemia. (1B)
3.1.17: We suggest that target HbA1c be extended above
7.0% (53 mmol/mol) in individuals with comorbidities
or limited life expectancy and risk of hypoglycemia.
(2C)
3.1.18: In people with CKD and diabetes, glycemic control
should be part of a multifactorial intervention
strategy addressing blood pressure control and car-
diovascular risk, promoting the use of angiotensin-
converting enzyme inhibition or angiotensin
receptor blockade, statins, and antiplatelet therapy
where clinically indicated. (Not Graded)Commentary
Although evidence supporting intensive glycemic
control in type 2 diabetes consistently demonstrates a
reduced rate of microvascular complications, the time
until beneﬁt is long. In the ACCORD Study, a median
treatment duration of 3.7 years was required to reduce
incident microalbuminuria or macroalbuminuria.91 In
other studies, the time until beneﬁt was even longer,
ranging from 5.5 to 14 years.92-94 Reduction in the
progression of existing microalbuminuria was
demonstrated in the Veterans Affairs Cooperative
Study on Glycemic Control and Complications in
Type 2 Diabetes Feasibility Trial, with a time until
beneﬁt of 2 years.95 In all these trials, control groups
maintained at less stringent hemoglobin A1c (HbA1c)
levels (7.3%-9.4%) had rates of diabetic complica-
tions that were similar to treatment groups for many
years. As the burden of comorbidity and functional
impairment increases, the expected survival beneﬁt of
intensive glycemic control diminishes because of
competing risk. A decision analysis quantiﬁed the
expected increase in survival from more stringentAm J Kidney Dis. 2015;65(2):177-205
CSN CommentaryHbA1c control: an increase of 106 days in quality-
adjusted life-years in people aged 60 to 64 years
who were in good health (these patients had a life
expectancy of 14.6 years), an increase of 44 days in
those with some comorbidity (life expectancy, 9.7
years), and an increase of just 8 days with more
substantial comorbidity (life expectancy, 4.8 years).96
Finally, age has been shown to be an independent risk
factor for hypoglycemia with intensive glycemic
control.97 Synthesizing this evidence, we suggest a
target HbA1c between 7.0% and 8.5%, depending
on patient characteristics and values.
Sodium Intake3.1.19: We recommend lowering salt intake to ,90 mmol
(,2 g) per day of sodium (corresponding to 5 g of
sodium chloride) in adults, unless contraindicated
(see rationale). (1C)
3.1.19.1: We recommend restriction of sodium intake for
children with CKD who have hypertension (systolic
and/or diastolic blood pressure .95th percentile)
or prehypertension (systolic and/or diastolic blood
pressure .90th percentile and ,95th percentile),
following the age-based Recommended Daily
Intake. (1C)
3.1.19.2: We recommend supplemental free water and
sodium supplements for children with CKD and
polyuria to avoid chronic intravascular depletion
and to promote optimal growth. (1C)Commentary
We concur with recommendation 3.1.19.2. With
respect to recommendations 3.1.19 and 3.1.19.1,
although reducing sodium intake to the level recom-
mended by the guideline (,90 mmol of sodium
[equivalent to ,2 g of sodium or ,5 g of salt] with
no lower bound), in both the general population and
people with CKD, is known to reduce BP and mea-
sures of proteinuria, the evidence on the effects on
progression of GFR or ESRD is limited. The best
evidence comes from 2 observational studies that re-
ported: (1) no difference in ESRD or cardiovascular
outcomes across 3 tertiles of sodium intake in patients
not on ARBs98 and (2) an increased risk of progres-
sion to ESRD in the highest third of sodium intake
(mean sodium level, 5.3 g/d) compared with the
middle third (mean level, 4.1 g/d), but no difference
between the middle and lowest thirds.99 A systematic
review (published since the KDIGO guideline) re-
ported a consistent association between high sodium
intake (.4.6 g/d) and adverse renal outcomes, but the
association between low (,2.3 g/d) versus moderate
(2.3-4.6 g/d) was inconsistent.100 Also published
since the KDIGO guideline, a large observational
study conducted in patients at high vascular risk
showed no relationship between sodium intake and
either progressive loss of GFR or progression ofAm J Kidney Dis. 2015;65(2):177-205proteinuria.101 To date, no adequately powered long-
term randomized clinical trial has evaluated the causal
relationship between sodium intake and renal
outcomes.100
In terms of important nonrenal outcomes, studies of
mostly nonrenal populations with and without hy-
pertension were summarized in a meta-analysis of
studies published in or before 2011, performed for the
World Health Organization Nutrition Guidance
Expert Advisory Group Subgroup on Diet and Health.
In trials reducing sodium intake compared with con-
trol or no intervention, systolic BP decreased by 3.4
(95% CI, 2.5-4.3) mm Hg, and diastolic BP, by 1.5
(95% CI, 0.98-2.1) mm Hg.102 Reductions of this
magnitude would be expected to reduce heart disease
and stroke; in the same review, higher sodium intake
was associated with increased risk of stroke and fatal
stroke (risk ratios of 1.24 [95% CI, 1.08-1.43] and
1.63 [95% CI, 1.27-2.10], respectively), inconclusive
effects on cardiovascular disease or coronary heart
disease (risk ratios of 1.12 [95% CI, 0.93-1.34] and
1.04 [95% CI, 0.86-1.24], respectively), and an
increased risk of fatal coronary heart disease events
(risk ratio, 1.32; 95% CI, 1.13-1.53). Recent pro-
spective cohort studies reported a J-shaped associa-
tion between sodium intake and cardiovascular
disease. A study of a secondary prevention population
(n 5 28,880) reported the lowest cardiovascular dis-
ease risk at 4 to 6 g/d of sodium, intakes , 3 g (HR,
1.19; 95% CI, 1.02-1.39) and .7 g (HR, 1.53; 95%
CI, 1.26-1.86) associated with increased risk of car-
diovascular mortality,103 and no relationship with loss
of GFR or ESRD or progression of proteinuria.101 A
second study, of patients with type 1 diabetes
(n 5 2,807), reported a similar J-shaped association
with all-cause mortality.104 Three other prospective
cohort studies have reported inverse associations with
increased risk of cardiovascular death with low intake
of sodium.105-107
In summary, evidence from the literature indicates
reductions in sodium intake lead to lower BP in the
general population and in people with hypertension,
who are the subject of general recommendations;
however, population recommendations are beyond
the scope of the guideline. We recognize that practi-
tioners may wish, for consistency, to give advice to
patients with renal disease that is aligned with popu-
lation health recommendations and standard preven-
tative practice (Health Canada recommends 1.5 g/d as
an adequate intake and 2.3 g/d as a tolerable upper
limit108; the Canadian Hypertension Education Pro-
gram recommends “reducing towards” 2.0 g/d).
However, consideration of the direct evidence
available in renal populations and populations
with vascular disease led us to different conclusions
about what we could consider an evidence-based189
Akbari et altherapeutic diet for patients with CKD. In general,
among people with renal disease, those who had
the fewest outcomes were those with mean urinary
sodium excretion corresponding to intakes of 2.7 to
3.3 g/d,98,99,100 compared with higher intakes.
Accepting that these observational data are low-
quality evidence on which to base a recommen-
dation for therapy, we suggest reducing sodium
intake in patients whose estimated intake greatly
exceeds these values. We do not support the
recommendation of ,2 g/d because of the absence of
evidence for this threshold. Alternative interventions
are available to reduce BP that have been shown to
reduce clinically important outcomes, and there are
the possibilities of harm from malnutrition and from
the social, cultural, and ﬁnancial difﬁculties associ-
ated with changes from a person’s normal diet. We
recognize and respect the opinions of other commit-
tees, including the CSN commentary on BP man-
agement,68 which was independent of our committee.
With respect to resistant hypertension or edema, a
recent randomized crossover trial in hypertensive
patients with stage 3 to 4 CKD who were counseled
by a dietitian to follow a low-sodium diet (,2.3 g/d)
and then randomly assigned to receive either
120 mmol/d of sodium versus placebo (ie, ,2.3 g/
d vs 5 g/d) showed signiﬁcant short-term changes in
BP, kidney function, and ﬂuid parameters, favoring
the lower sodium diet over 2 weeks,109 but no long-
term data are available. Optimal sodium restriction
for those with resistant hypertension or edema is not
known.
Implications Within Canadian Health Care
In the developed world, much of the population
sodium consumption derives from processed food.110
In Canada, nearly 80% of sodium intake is attribut-
able to the use of processed and restaurant foods, and
average sodium intake of Canadians is estimated to be
3.4 g/d.108 Therefore, we believe the focus of di-
etary sodium reduction should be placed on
reducing the consumption of processed and
restaurant foods, which has the additional beneﬁt of
avoiding phosphate additives. We also recommend
encouraging patients to choose lower-sodium alter-
natives at the point of food purchase rather than to
discourage the use of salt in cooking. This likely
would aid patients to choose a diet higher in fresh
fruits and vegetables, which is also consistent with the
observational data that diets rich in fruit and vegeta-
bles are associated with better renal outcomes (section
3.1.4). However, we recognized that some frail but
independent elderly people may rely on processed
food and that for them, other options may not be
feasible. The focus for patients with poor intake of
food and declining health should be to avoid dietary190restrictions in the hope of encouraging better food
intake and reducing the risk or progression of
malnutrition.
Hyperuricemia and Lifestyle3.1.20: There is insufficient evidence to support or refute the
use of agents to lower serum uric acid concentra-
tions in people with CKD and either symptomatic
or asymptomatic hyperuricemia in order to delay
progression of CKD. (Not Graded)
3.1.21: We recommend that people with CKD be encour-
aged to undertake physical activity compatible
with cardiovascular health and tolerance (aiming for
at least 30 minutes 5 times per week), achieve
a healthy weight (BMI 20 to 25, according to country
specific demographics), and stop smoking. (1D)Commentary
We concur with recommendation statements 3.1.20
and 3.1.21.
Additional Dietary Advice3.1.22: We recommend that individuals with CKD receive
expert dietary advice and information in the context
of an education program, tailored to severity of CKD
and the need to intervene on salt, phosphate, po-
tassium, and protein intake where indicated. (1B)Implications Within Canadian Health Care
Access to dietitian support is generally good in
Canada, but current resources would not permit long-
term supervision, or even assessment, of all people
with CKD. However, in remote areas, there are
Canadians who would not have easy access to su-
pervision by a dietitian. Not adopting protein re-
striction routinely in patients with CKD avoids the
unintended but inevitable consequence of redirection
of this limited resource away from those (with and
without CKD) who receive speciﬁc referral on the
basis of ability to beneﬁt.
A more liberal suggestion about sodium intake
and protein intake may enhance quality of life and
adherence,111 as well as reducing the proportion of pa-
tients who would be advised to make changes. Patients
with GFRs. 30 mL/min/1.73 m2 rarely experience
hyperphosphatemia, acidosis, or hyperkalemia.112,113
Though hyperparathyroidism occurs in 25% to 60% of
patients with GFRs of 30 to 60 mL/min/1.73 m2,113
there is no direct evidence that managing hyperpara-
thyroidism through diet in patients with GFR. 30 mL/
min/1.73 m2 prevents clinically important outcomes.
Our focus in detection and dietary management of these
problems can appropriately remain on the fewer patients
with GFRs, 30 mL/min/1.73 m2.
We recognize the ﬁnancial costs to patients
for special diets, particularly to those living in
northern communities. We also recognize the
cultural and societal importance of food to ourAm J Kidney Dis. 2015;65(2):177-205
CSN CommentaryFirst Nations’ people and all Canadians, and we
acknowledge the potential negative outcome of
over-restrictive therapeutic dietary regimens. We
suggest that clinicians take into account cultur-
ally appropriate and individualized approaches
to nutritional interventions, whenever possible,
when they advise their patients on dietary habits.
This will likely enhance compliance114 and limit
potential adverse outcomes as a result of evoking
fear of food in patients and over-restricting their
intake.
Anemia
Definition and identification of anemia in CKD3.2.1: Diagnose anemia in adults and children .15 years
with CKD when the Hb concentration is ,13.0 g/dl
(,130 g/l) in males and ,12.0 g/dl (,120 g/l) in
females. (Not Graded)
3.2.2: Diagnose anemia in children with CKD if Hb concen-
tration is ,11.0 g/dl (,110 g/l) in children 0.5–5
years, ,11.5 g/dl (115 g/l) in children 5–12 years,
and ,12.0 g/dl (120 g/l) in children 12-15 years. (Not
Graded)AEvaluation of anemia in people with CKD3.2.3: To identify anemia in people with CKD measure Hb
concentration (Not Graded):m J Ki whenclinically indicated inpeoplewithGFR$ 60 ml/
min/1.73 m2 (GFR categories G1-G2);
 at least annually in people with GFR 30–59 ml/min/
1.73 m2 (GFR categories G3a-G3b);
 at least twice per year in people with GFR , 30 ml/
min/1.73 m2 (GFR categories G4-G5).Commentary
We concur with recommendations 3.2.1 and 3.2.2,
but note that these are thresholds for the identiﬁcation
of the problem, not for treatment. Recommendation
3.2.3 concerns screening for anemia in patients with
CKD. As .50% of patients with GFRs , 30 mL/
min/1.73 m2 have anemia,1(p81) we suggest
screening for anemia in these patients, and if
identiﬁed, further clinical evaluation of the contrib-
uting causes for these patients, but the optimal fre-
quency of rescreening will depend on the patient’s
comorbidities, GFR, and hemoglobin. There is
insufﬁcient evidence to provide suggestions or
recommendations on the minimum frequency of
hemoglobin remeasurement, beyond the applica-
tion of clinical judgment, and no evidence to sup-
port annual screening in people with GFRs of 30 to
59 mL/min/1.73 m2. Management of anemia is dis-
cussed in the CSN commentary on the KDIGO ane-
mia guideline.115
Metabolic Bone Disease3.3.1: We recommend measuring serum levels of calcium,
phosphate, PTH, and alkaline phosphatase activity atdney Dis. 2015;65(2):177-205least once in adults with GFR,45 ml/min/1.73 m2
(GFR categories G3b-G5) in order to determine
baseline values and inform prediction equations if
used. (1C)
3.3.2: We suggest not to perform bone mineral density
testing routinely in those with eGFR,45 ml/min/
1.73 m2 (GFR categories G3b-G5), as information
may be misleading or unhelpful. (2B)Commentary
We concur with recommendation 3.3.2. With
respect to recommendation 3.3.1, in 2 large cohorts
(NHANES [National Health and Nutrition Examina-
tion Survey] and KEEP [Kidney Early Evaluation
Program]) of participants with eGFRs , 45 mL/min/
1.73 m2, calcium values were in the normal range in
89% and 92%, respectively, and phosphorus values
were in the normal range in 87% and 90%, respec-
tively.116 While abnormal parathyroid hormone
(PTH) values were more prevalent (36% and 31%
within normal range), it is unlikely that their recog-
nition is important as treatment for abnormal PTH
values have not been demonstrated to affect clinically
important outcomes, even in those with advanced
CKD or ESRD. There is insufﬁcient evidence to
provide any general suggestion on the need to
screen for metabolic bone disease in patients with
CKD and GFRs . 30 mL/min/1.73 m2.
Laboratory abnormalities reﬂecting metabolic
bone disease are more prevalent in patients with
GFRs, 30 mL/min/1.75 m2.116 We suggest screening
these patients, and rescreening depending on comor-
bidity, GFR, and the values observed on the ﬁrst
occasion, though we recognize that evidence-based
strategies for the management of these abnormalities
are not available.
Target Serum Phosphate Levels3.3.3: In people with GFR,45 ml/min/1.73 m2 (GFR cate-
gories G3b-G5), we suggest maintaining serum
phosphate concentrations in the normal range
according to local laboratory reference values. (2C)Commentary
There is insufﬁcient evidence to recommend the
measurement or clinical targets for serum phos-
phate in people with GFRs , 45 mL/min/1.75 m2.
Elevated serum phosphate is associated with
increased mortality and vascular and valvular calci-
ﬁcation; however, achievement of clinical targets for
these parameters over time has not been associated
with improved survival in ESRD populations.117 With
the exception of advice to avoid processed food
because of the prevalence of phosphate additives,
restricting to low-phosphate foods is difﬁcult without
incurring protein restriction, which may lead to191
Akbari et almalnutrition and adverse outcomes (see recommen-
dation 3.1.3).
Calcium-based phosphate binders are widely used
and inexpensive compared with non–calcium-based
phosphate binders, but a 2013 meta-analysis of
4,622 patients in 11 randomized controlled trials
suggested an increase in mortality from their use,
compared with non–calcium-based binders.118 This
meta-analysis is limited by evidence of publication
bias118,119: Duval’s trim and ﬁll analysis, which adjusts
for publication bias, resulted in loss of statistical sig-
niﬁcance for the adjusted intervention effect (0.82;
95% CI, 0.64-1.04).119 Exclusion of small studies
(,50 events) resolves heterogeneity, attenuates the
effect size, and results in loss of statistical signiﬁcance
(RR, 0.93; 95% CI, 0.82-1.04).119 Furthermore, inter-
pretation of the study is also problematic because of a
lack of placebo controls: were we to give credit to the
results, we do not know whether they mean that
calcium-containing binders are harmful (compared to
no intervention) or that sevelamer, the most extensively
studied noncalcium binder, is beneﬁcial (compared to
no intervention). Because of these uncertainties, we are
unable to make a recommendation or a suggestion in
this area: either using or not using phosphate binders
and either using a calcium-containing or non–calcium-
containing binder are reasonable.
Optimal PTH Level3.3.4: In people with GFR ,45 ml/min/1.73 m2 (GFR cate-
gories G3b-G5) the optimal PTH level is not known.
We suggest that people with levels of intact
PTH above the upper normal limit of the assay are
first evaluated for hyperphosphatemia, hypocalcemia,
and vitamin D deficiency. (2C)Commentary
There is insufﬁcient evidence to suggest the
measurement or clinical targets for hyperpho-
sphatemia, hypocalcemia, and high PTH in people
with GFRs , 45 mL/min (see previous comments on
recommendation 3.3.3). The course of action outlined
or a less active approach are both reasonable.
Nutritional Vitamin D and Calcitriol3.3.5: We suggest not to routinely prescribe vitamin D
supplements or vitamin D analogs, in the absence
of suspected or documented deficiency, to suppress
elevated PTH concentrations in people with CKD
not on dialysis. (2B)Commentary
We agree that there is no randomized evidence of
clinically important beneﬁt from suppression of PTH
in patients with CKD, either by nutritional or acti-
vated (hydroxylated) vitamin D.192The guideline is silent on the appropriate use of
both nutritional vitamin D and hydroxylated vitamin
D as nutritional supplements in patients with CKD.
Vitamin D (cholecalciferol) is an essential nutritional
compound, and its deﬁciency in the diet leads to
nutritional-related deﬁciency diseases such as rickets
and osteomalacia.120 Many populations in the devel-
oped world have a high prevalence of vitamin D
deﬁciency (eg, 32% of Canadians).121 Because the
prevalence of deﬁciency and insufﬁciency are higher
in people with CKD than in the general population122
and lower levels are associated with mortality in
people with CKD,123 routine supplementation at a
higher dose than the general population recommen-
dation has been suggested (4,000 rather than
1,000 IU/d).124 A meta-analysis of observational and
randomized studies of nutritional vitamin D in ther-
apeutic doses (w10,000 IU/d) showed increases in
serum vitamin D levels in all CKD stages, reduction
in PTH, and minimal effect on serum calcium and/or
phosphate levels.125
Activated vitamin D (1,25-dihydroxyvitamin D;
calcitriol) is a hormone with speciﬁc endocrine
functions, including PTH suppression, and needs to
be clearly distinguished from its precursor, the nutri-
tional compound cholecalciferol. Circulating calcitriol
derives at least in part from renal 1a-hydroxylation
from the precursor, but it is also hydroxylated locally
in other tissues, where it produces autocrine and
paracrine effects.124 These effects have been impli-
cated in immune function, prevention of malignancy,
and reduced cardiovascular disease occurrence in
people with and without CKD.123,124,126
Because of reduced renal hydroxylation, calcitriol
deﬁciency is prevalent in patients with CKD and is
thought to contribute to hyperparathyroidism, meta-
bolic bone disease, and perhaps vascular calciﬁcation,
though serum levels do not correlate with markers of
metabolic bone disease.127 A meta-analysis of vitamin
D analogues, such as calcitriol, used pharmacologi-
cally showed uncertain reductions in PTH and in-
creases in calcium and phosphate levels. Clinically
important renal outcomes could not be assessed.
Because randomized studies of clinically important
outcomes are lacking, we were not able to recommend
the use of nutritional vitaminD, alfacalcidol, or calcitriol
in patients with CKD. Derangements of the bone and
calciﬁcation systems are less prevalent and severe in
patients with GFRs. 30 mL/min/1.73 m2, and we
suggest following general population recommenda-
tions for supplementation of nutritional vitamin D
(range of 800-1,000 IU daily)128,129 without routine
measurement of PTH or vitaminD levels. In patients
with GFRs, 30 mL/min/1.73 m2, either supple-
menting, or not supplementing, at doses up to
w4,000 IU daily are both reasonable, based onAm J Kidney Dis. 2015;65(2):177-205
CSN Commentaryclinical judgment and the patient’s preferences. The
use of alfacalcidol or calcitriol as a nutritional sup-
plement in patients with CKD is supported even less
by evidence of beneﬁt, though there is strong
evidence of deﬁciency, especially in those with the
lowest levels of GFR.130 We consider either using or
not using these analogues to be reasonable.
Bisphosphonates in People With CKD3.3.6: We suggest not to prescribe bisphosphonate treat-
ment in people with GFR,30 ml/min/1.73 m2 (GFR
categories G4-G5) without a strong clinical rationale.
(2B)Commentary
We concur with this recommendation; because this
is a prophylactic measure that has no evidence for
beneﬁt in people at this range of GFR, it was difﬁcult
to understand what might ever constitute a strong
clinical rationale for using it.
Acidosis3.4.1: We suggest that in people with CKD and serum bi-
carbonate concentrations ,22 mmol/l treatment with
oral bicarbonate supplementation be given to main-
tain serum bicarbonate within the normal range,
unless contraindicated. (2B)Commentary
Lower serum bicarbonate is associated with more
rapid progression,131 and one small randomized
controlled trial suggests that treating patients with
eGFRs , 30 mL/min/1.73 m2 and serum bicarbonate
concentrations , 20 mmol/L may decrease progres-
sion of CKD.132 This ﬁnding needs to be conﬁrmed in
other clinical trials, but the intervention is safe in most
clinical contexts. Either prescribing or not pre-
scribing bicarbonate is reasonable. Bicarbonate is
unpalatable to some patients and in tablet form incurs
expense. Substitution of baking soda from a food
store (1/4 teaspoon h 1 g of sodium bicarbonate)
may be helpful.
OTHER COMPLICATIONS OF CKD
Patients With CKD and Cardiovascular Disease4.1.1: We recommend that all people with CKD be consid-
ered at increased risk for cardiovascular disease. (1A)
4.1.2: We recommend that the level of care for ischemic
heart disease offered to people with CKD should not
be prejudiced by their CKD. (1A)
4.1.3: We suggest that adults with CKD at risk for athero-
sclerotic events be offered treatment with antiplatelet
agents unless there is an increased bleeding risk
that needs to be balanced against the possible car-
diovascular benefits. (2B)
4.1.4: We suggest that the level of care for heart failure
offered to people with CKD should be the same as is
offered to those without CKD. (2A)Am J Kidney Dis. 2015;65(2):177-2054.1.5: In people with CKD and heart failure, any escalation
in therapy and/or clinical deterioration should
prompt monitoring of eGFR and serum potassium
concentration. (Not Graded)Commentary
We concur with recommendation 4.1.1.
With respect to the recommendation 4.1.2 regarding
patients with ischemic heart disease, we agree that
there are observational data to support improved health
outcomes in people with CKD by offering them the
same standard of care for ischemic heart disease as in
the general population.133-135 However, there are some
considerations in people with CKD that may appro-
priately alter their care. For example, in patients with
low GFRs at high risk of contrast-induced nephropa-
thy and stable ischemic heart disease, clinical judg-
ment is required in terms of timing of angiography and
revascularization. In patients with CKD who have
made an advance decision not to receive kidney
replacement therapies to manage kidney failure, more
conservative approaches to managing ischemic heart
disease may be chosen.
Regarding recommendation 4.1.3 concerning anti-
platelet medications, patients with low GFRs are
generally at increased bleeding risk,136 and anti-
platelet medications increase the risk of major
bleeding by 33%.137 There is uncertain beneﬁt of
antiplatelet agents in people with GFRs , 15 mL/
min/1.73 m2.138 Either prescribing or not pre-
scribing antiplatelet medication to patients with
stable vascular disease and CKD is reasonable.
We concur with recommendations 4.1.4 to 4.1.5.
N-Terminal Pro–Brain Natriuretic Peptide and
Troponin4.2.1: In people with GFR,60 ml/min/1.73 m2 (GFR cate-
gories G3a-G5), we recommend that serum concen-
trations of BNP/NT-proBNP be interpreted with caution
and in relation to GFR with respect to diagnosis of
heart failure and assessment of volume status. (1B)
4.2.2: In people with GFR,60 ml/min/1.73 m2 (GFR cate-
gories G3a-G5), we recommend that serum concen-
trations of troponin be interpreted with caution
with respect to diagnosis of acute coronary syndrome. (1B)Commentary
We concur with recommendation 4.2.1. With
respect to recommendation 4.2.2, though the diag-
nostic test accuracy of the elevated troponin for acute
coronary syndrome in patients with CKD is not
optimal, it has a very good prognostic accuracy.
Elevated troponin in patients with CKD is actually
more predictive than in patients without CKD139 of
myocardial infarction and death within 30 days
(adjusted ORs of 2.5 [95% CI, 1.8-3.3] and 1.7 [95%
CI, 1.3-2.2], respectively).193
Table 1. Summary of Accuracy of Noninvasive Testing in Pretransplantation CKD Patients
Noninvasive Cardiac Testing No. of Studies Sensitivity (95% CI) Specificity (95% CI)
Dobutamine stress echocardiography 11173-183 0.44 (0.27-0.62) to 0.96 (0.78-1.00) 0.60 (0.36-0.81) to 1.00 (0.81-1.00)
Myocardial perfusion scintigraphy 7174,177,184-188 0.29 (0.08-0.58) to 0.92 (0.62-1.00) 0.50 (0.16-0.84) to 0.88 (0.69-0.97)
Exercise stress electrocardiography 2182,189 0.36 (0.21-0.54) to 1.00 (0.29-1.00) 0.00 (0.00-0.97) to 0.91 (0.83-0.96)
Exercise ventriculography 1187 0.50 (0.23-0.77) 0.67 (0.43-0.85)
Digital subtraction fluorography 1186 0.78 (0.61-0.90) 0.66 (0.51-0.79)
Abbreviations: CI, confidence interval; CK D, chronic kidney disease.
Akbari et alNoninvasive Cardiac Testing4.2.3: We recommend that people with CKD presenting
with chest pain should be investigated for underlying
cardiac disease and other disorders according to
the same local practice for people without CKD (and
subsequent treatment should be initiated similarly).
(1B)
4.2.4: We suggest that clinicians are familiar with the
limitations of non-invasive cardiac tests (e.g., exercise
electrocardiography [ECG], nuclear imaging, echo-
cardiography, etc.) in adults with CKD and interpret
the results accordingly. (2B)Commentary
Most of the literature about evaluation for coronary
artery disease in patients with CKD comes from the
evaluation of kidney transplant candidates. In these
studies, a majority of patients already have ESRD or
an advanced stage of CKD. Reports of diagnostic test
accuracy (sensitivity and speciﬁcity) of noninvasive
cardiac testing in patients with CKD are highly vari-
able (inconsistent); however, all the widely used
noninvasive tests are generally less accurate (typically
less sensitive and less speciﬁc) in patients with
advanced CKD than in those without. Table 1 sum-
marizes the test accuracy for available noninvasive
cardiac testing in patients with CKD based on our
data extraction from papers identiﬁed in a 2011 sys-
tematic review.
Peripheral Artery Disease4.3.1: We recommend that adults with CKD be regularly
examined for signs of peripheral arterial disease
and be considered for usual approaches to therapy.
(1B)Commentary
We do not concur that all adults with CKD
should be regularly examined for peripheral ar-
tery disease. We are not aware of any studies
showing health beneﬁt from periodic examination in
this area. We also noted that the diagnostic test ac-
curacy of commonly used studies like ankle-brachial
index is questionable in CKD populations because
of the increased prevalence of vessel calciﬁcation.140194Regular Podiatric Assessment4.3.2: We suggest that adults with CKD and diabetes are
offered regular podiatric assessment. (2A)Commentary
If health care resources permit, we concur,
though we acknowledge that no direct evidence
shows that podiatry referral changes outcomes in
patients with CKD. This recommendation is based
on current widely accepted best practices, on an
extrapolation from the assumed beneﬁt of podiatry
referral in patients with diabetes, in addition to the
known increased risk of ulcers and amputations in
patients with CKD, especially those who also have
diabetes.
Adjusting Drug Doses for Renal Clearance4.4.1: We recommend that prescribers should take GFR into
account when drug dosing. (1A)
4.4.2: Where precision is required for dosing (due to narrow
therapeutic or toxic range) and/or estimates may
be unreliable (e.g., due to low muscle mass), we
recommend methods based upon cystatin C or
direct measurement of GFR. (1C)Commentary
We concur with recommendation 4.4.2. With
respect to recommendation 4.4.1, there are limitations
to the different estimating GFR equations when used
for drug dosing.141 Some pharmacokinetic studies
have excluded patients with decreased kidney func-
tion, making it difﬁcult to assess drug dosing in these
patients. Furthermore, when pharmacokinetic studies
have been performed, kidney function was, in the
past, usually estimated using the Cockcroft-Gault
equation.142 Although the MDRD Study and CKD-
EPI equations have been validated in large pop-
ulations for assessing renal function, all estimating
equations for GFR have their limitations, perhaps the
greatest being their residual inaccuracy (eg, for CKD-
EPI, 13% of estimates differ from measured GFR by
.30%).17 However, measuring GFR directly, though
more accurate, is rarely practical and is costly, so we
focus on how best to use the equations.Am J Kidney Dis. 2015;65(2):177-205
CSN CommentaryIt is important to recognize that both the MDRD
Study and CKD-EPI equations estimate GFR
normalized to body surface area, which is useful in
assessing the presence of kidney disease and sum-
marizing across populations, whereas what is
needed for drug dosing is an estimate of absolute
clearance (ie, in milliliters per minute, not milliliters
per minute per 1.73 m2). Using CKD-EPI–estimated
GFR to guide drug dosing may lead to underdosing
larger people and overdosing smaller people or people
with amputations. We recommend back calculation
to an absolute clearance (using an anthropometric
estimate of the patient’s body surface area) in
people who are clearly larger or smaller than the
average 1.73-m2 person. When absolute clearances
calculated from MDRD Study equation estimates were
compared with measured GFR, with Cockcroft-Gault
and with ideal-body-weight Cockcroft-Gault, concor-
dance (percentage agreement on the stratum of kidney
function) was 75% to 78%.143 Monitoring of patients’
responses to treatment, renal function in the case of
nephrotoxic drugs, and drug levels when applicable is
essential.
Sick-Day Rules: Advice to Stop Certain Medications
When Risk for AKI is High4.4.3: We recommend temporary discontinuation of
potentially nephrotoxic and renally excreted drugs in
people with a GFR ,60 ml/min/1.73 m2 (GFR
categories G3a-G5) who have serious intercurrent
illness that increases the risk of AKI. These
agents include, but are not limited to: RAAS
blockers (including ACE-Is, ARBs, aldosterone
inhibitors, direct renin inhibitors), diuretics,
NSAIDs, metformin, lithium, and digoxin. (1C)Commentary
We concur with recommendation 4.4.3. Though
direct evidence of beneﬁt of this strategy is lacking, it
is highly likely that continuing these agents under
these circumstances would lead to harm, and possible
that some patients will be able to learn sick-day rules
and beneﬁt from them.
Nonprescription Medications and Herbal Products4.4.4: We recommend that adults with CKD seek medical
or pharmacist advice before using over-the-counter
medicines or nutritional protein supplements. (1B)
4.4.5: We recommend not using herbal remedies in people
with CKD. (1B)Commentary
We concur with recommendation 4.4.4. Patients
should always check with pharmacists when purchas-
ing over-the-counter products as many products
contain ingredients that can accumulate (eg, magne-
sium supplements and phosphate-containing laxatives)Am J Kidney Dis. 2015;65(2):177-205or cause nephrotoxicity (especially nonsteroidal anti-
inﬂammatory drugs) in patients with CKD. With
respect to recommendation 4.4.5, although herbal
products are commonly used, their pharmacokinetics
and pharmacodynamics in patients with CKD have not
been well studied. However, there are many case re-
ports with various herbal products causing nephrotox-
icity and therefore these agents should be avoided in all
patients.144
Implications Within Canadian Health Care
Canada is a multicultural society and we recognize
that many patients may have cultural and spiritual
practices that involve herbs about which little is
known in our Western medical model. We recom-
mend respectful negotiation with patients and families
over these issues.
Metformin, Lithium, and Calcineurin Inhibitors4.4.6: We recommend that metformin be continued in peo-
ple with GFR $45 ml/min/1.73 m2 (GFR categories
G1-G3a); its use should be reviewed in those
with GFR 30–44 ml/min/1.73 m2 (GFR category G3b);
and it should be discontinued in people with
GFR,30 ml/min/1.73 m2 (GFR categories G4-G5).
(1C)
4.4.7: We recommend that all people taking potentially
nephrotoxic agents such as lithium and calcineurin
inhibitors should have their GFR, electrolytes and
drug levels regularly monitored. (1A)Commentary
We concur with recommendation 4.4.7. With
respect to recommendation 4.4.6, metformin is renally
excreted and its clearance is proportional to GFR.We
suggest dose reduction in proportion to the
GFR.145-148
Based on indirect evidence, we suggest that pa-
tients be advised not to take metformin on days
when they may experience AKI: for example,
around surgery, angiography, and if they are unwell at
home (sick-day rules; in keeping with 4.4.3).
GFR of 30 to 60 mL/min/1.73 m2. We agree that
metforminmay be used in patients with GFRs as low as
30 mL/min/1.73 m2. In a Cochrane meta-analysis of
347 studies, therewas no case of lactic acidosis in either
70,490 metformin patient-years or 55,451 non-
metformin patient-years.149 This review concluded that
there is no evidence from trials or cohort studies that
metformin is associated with an increased risk of lactic
acidosis, or with increased levels of lactate, compared
with other antihyperglycemic agents. In patients with
creatinine clearances , 40 mL/min, plasma concen-
trations of lactate did not correlate with metformin
concentrations or metformin dose.150 In 1,572 patients
with GFRs of 30 to 60 mL/min/1.73 m2, metformin
use, compared with other glucose-lowering therapies,
was associated with a reduction in 2-year mortality;195
Akbari et albeneﬁt was greater in this group than in patients with
GFRs . 60 mL/min/1.73 m2.151 In the Swedish Na-
tional Diabetes Register (n 5 51,675), risk of mortality
was reduced in patients with eGFRs of 45 to 60 mL/
min/1.73m2 and those with eGFRs . 60 mL/min/1.73
m2 and was the same in patients with eGFRs of 30 to
45 mL/min/1.73 m2.152
GFR less than 30 mL/min/1.73 m2. We do not
know how many patients with GFRs , 30 mL/min/
1.73 m2 have been studied. In the trials summarized in
the Cochrane meta-analysis, renal insufﬁciency was
usually deﬁned as creatinine . 133 mmol/L and was a
contraindication in many studies. However, in 143 of
the 334 (53%) prospective studies, accounting for
37,360 patient-years of metformin use, there was no
exclusion on the basis of renal insufﬁciency.149 No
cases of lactic acidosis were identiﬁed in this subset.
In 393 patients with creatinine levels of 133 to
220 mmol/L, many of whom had additional comor-
bidity or relative contraindications to metformin,
randomization to continuingmetformin comparedwith
changing to alternative agents led to no case of lactic
acidosis in 690 patient-years of follow-up. Metformin
was discontinued if creatinine was .220 mmol/L
(corresponding to GFR ofw23 mL/min/1.73 m2).153
The demonstrated cardiovascular beneﬁt in over-
weight patients154 is a strong reason to use metformin
in patients with type 2 diabetes. It is effective in
lowering blood glucose, has a negligible risk of hy-
poglycemia, and does not cause weight gain.
We consider it reasonable to use metformin, in
an appropriately adjusted dose, in selected pa-
tients with a GFR , 30 mL/min/1.73 m2. Patients
should have relatively stable renal function, be at
low risk for AKI, and be likely to comply with
sick-day rules; obese patients may beneﬁt most.
Because the direct evidence is limited, this is not a
recommendation or a suggestion.
When resources permit, renally adjusted doses of
sitagliptin may be a useful and safe alternative, which
like metformin is not associated with weight gain.155
However, in patients who are beyond monotherapy,
metformin may be combined with sitagliptin for ad-
ditive hypoglycemic effects.156 Two studies of sita-
gliptin in a total of 517 patients with diabetes and
CKD have been conducted and reported outcomes
similar to those observed in studies in unselected
patients with diabetes,157,158 but recommendations
about safety in CKD are based on pharmacokinetics
more than on extensive experience.159
People With CKD and Cancer4.4.8: People with CKD should not be denied therapies for
other conditions such as cancer but there should
be appropriate dose adjustment of cytotoxic drugs
according to knowledge of GFR. (Not Graded)196Commentary
In addition, low GFR may represent an important
comorbidity and risk factor for adverse outcomes that
should be considered in the overall treatment plan.
Imaging Studies4.5.1: Balance the risk of acute impairment in kidney
function due to contrast agent use against the diag-
nostic value and therapeutic implications of the
investigation. (Not Graded)Radiocontrast4.5.2: We recommend that all people with GFR ,60 ml/min/
1.73 m2 (GFR categories G3a-G5) undergoing
elective investigation involving the intravascular
administration of iodinated radiocontrast media
should be managed according to the KDIGO Clinical
Practice Guideline for AKI including: Avoidance of high osmolar agents (1B);
 Use of lowest possible radiocontrast dose (Not
Graded);
 Withdrawal of potentially nephrotoxic agents
before and after the procedure (1C);
 Adequate hydration with saline before, during, and
after the procedure (1A);
 Measurement of GFR 48–96 hours after the pro-
cedure (1C).Gadolinium-based contrast media4.5.3: We recommend not using gadolinium-containing
contrast media in people with GFR ,15 ml/min/
1.73 m2 (GFR category G5) unless there is no alter-
native appropriate test. (1B)
4.5.4: We suggest that people with a GFR ,30 ml/min/
1.73 m2 (GFR categories G4-G5) who require
gadolinium containing contrast media are prefer-
entially offered a macrocyclic chelate preparation.
(2B)Bowel preparation4.5.5: We recommend not to use oral phosphate-containing
bowel preparations in people with a GFR ,60 ml/min/
1.73 m2 (GFR categories G3a-G5) or in those
known to be at risk of phosphate nephropathy. (1A)Commentary
We agree with these recommendations on the use of
imaging studies. In terms of the recommendation re-
garding radiocontrast, we advise referring to the CSN
commentary on the KDIGO AKI guideline.73
CKD and Risks for Infections, AKI, Hospitalizations,
and Mortality
CKD and risk of infections4.6.1: We recommend that all adults with CKD are offered
annual vaccination with influenza vaccine, unless
contraindicated. (1B)
4.6.2: We recommend that all adults with eGFR,30 ml/min/
1.73 m2 (GFR categories G4-G5) and those
at high risk of pneumococcal infection (e.g., nephrotic
syndrome, diabetes, or those receiving immunosup-
pression) receive vaccination with polyvalent
pneumococcal vaccine unless contraindicated. (1B)Am J Kidney Dis. 2015;65(2):177-205
CSN Commentary4.6.3: We recommend that all adults with CKD who have
received pneumococcal vaccination are offered
revaccination within 5 years. (1B)
4.6.4: We recommend that all adults who are at high risk
of progression of CKD and have GFR ,30 ml/min/
1.73 m2 (GFR categories G4-G5) be immunized
against hepatitis B and the response confirmed
by appropriate serological testing. (1B)
4.6.5: Consideration of live vaccine should include an
appreciation of the patient’s immune status and
should be in line with recommendations from official
or governmental bodies. (Not Graded)
4.6.6: Pediatric immunization schedules should be
followed according to official international and
regional recommendations for children with CKD.
(Not Graded)ACKD and risk of AKI4.6.7: We recommend that all people with CKD are consid-
ered to be at increased risk of AKI. (1A)
4.6.7.1: In people with CKD, the recommendations detailed
in the KDIGO AKI Guideline should be followed
for management of those at risk of AKI during
intercurrent illness, or when undergoing investiga-
tion and procedures that are likely to increase
the risk of AKI. (Not Graded)Commentary
We concur with recommendations 4.6.1 to 4.6.7.1
(though see comments concerning the implications
to Canadian health care for 4.6.1 and 4.6.4). With
respect to CKD and the risk of AKI, we advise
reviewing the CSN commentary on the KDIGO AKI
guideline.73
Implications Within Canadian Health Care
With respect to recommendation 4.6.1, inﬂuenza
vaccine is free in Canada for high-risk populations
(individuals with renal disease and diabetes mellitus,
infants, older adults, etc). Pneumococcal vaccine is
publicly funded for patients with CKD in all prov-
inces except Saskatchewan, where it is publicly
funded for transplant recipients.160 In Canada, these
vaccines would normally be given by the primary
care provider, which facilitates tracking and
revaccination.
With respect to recommendation 4.6.4, ﬁscal re-
sponsibility and cost-beneﬁt versus risk analysis
would place emphasis on immunizing those with
CKD most likely to choose and require future dialysis
or renal transplantation.161
CKD Management Programs4.6.8: CKD disease management programs should be
developed in order to optimize the community man-
agement of people with CKD and reduce the risk of
hospital admission. (Not Graded)
4.6.9: Interventions to reduce hospitalization and mortality
for people with CKD should pay close attention to
the management of associated comorbid conditions
and cardiovascular disease in particular. (Not Graded)m J Kidney Dis. 2015;65(2):177-205CommentaryThough observational evidence162-164 suggests that
earlier diagnosis permitting earlier intervention
through coordinated interdisciplinary CKD care is
associated with improved outcomes, including risk
reduction for mortality, such studies may be
confounded by selection bias. Although few in
number, interventional studies have indicated that a
comprehensive interdisciplinary approach to CKD
care can result in signiﬁcant improvements in overall
health care costs and quality of life. The Canadian
Prevention of Renal and Cardiovascular Endpoints
Trial (CanPREVENT)165 randomly assigned 236 pa-
tients with stages 3 to 4 CKD to usual care and
another 238 to a comprehensive nurse/nephrologist
care model that targeted kidney and cardiovascular
risk factors. Cost analysis was performed over a 2-
year period. The intervention group required fewer
resources and had a lower number of hospitalized
days and higher quality of life.
We agree that the development of interdisciplinary
clinical programs to improve outcomes (including
the reduction of AKI and admission to the hospital)
appears an important priority, but recognize the
limitations in the direct evidence of beneﬁt with re-
gard to hard outcomes from randomized trials. Any
beneﬁt is likely to be greatest in those with most
severe and complex disease and those at highest risk
for ESRD.
Implications Within Canadian Health Care
We recognize the resource-intensive nature of the
KDIGO recommendation concerning CKD disease
management programs and that supportive evidence
is limited and controversial. There was opinion-based
consensus that an interdisciplinary approach would be
most helpful for patients with eGFRs , 30 mL/min/
1.73 m2, complex comorbidity, or evidence of rapid
progression. Those with less signiﬁcantly decreased
eGFRs or isolated proteinuria can often be managed
in ofﬁce nephrology practice, by internists or endo-
crinologists, or in primary care, depending on the
clinical situation. We also recognize that in certain
Canadian regions, implementing these recommenda-
tions would require signiﬁcant shifts in current
models of care.
REFERRAL TO SPECIALISTS AND MODELS
OF CARE
Referral to Nephrologists5.1.1: We recommend referral to specialist kidney care
services for people with CKD in the following cir-
cumstances (1B): AKI or abrupt sustained fall in GFR;
 GFR,30 ml/min/1.73 m2 (GFR categories G4-
G5)*;197
198
Akbari et al A consistent finding of significant albuminuria
(ACR $300 mg/g [$30 mg/mmol] or
AER $300 mg/24 hours, approximately equivalent
to PCR$500 mg/g [$50 mg/mmol] or
PER $500 mg/24 hours);
 progression of CKD (see Recommendation 2.1.3
for definition);
 urinary red cell casts, RBC .20 per high power
field sustained and not readily explained;
 CKD and hypertension refractory to treatment with
4 or more antihypertensive agents;
 persistent abnormalities of serum potassium;
 recurrent or extensive nephrolithiasis;
 hereditary kidney disease.*If this is a stable isolated finding, formal referral
(i.e., formal consultation and ongoing care man-
agement) may not be necessary and advice from
specialist services may be all that is required to
facilitate best care for the patients. This will be
health-care system dependent.
Commentary
To date there has been no randomized controlled
trial to assess which patients would beneﬁt from
nephrology referral and such a trial would be hard to
conduct. Referral recommendations in the literature
are inconsistent.166 Moreover, referral also depends
upon the comfort of the patient’s primary care pro-
vider in managing CKD. We agree with a threshold
of GFR , 30 mL/min/1.73 m2 for referral to a
nephrologist, though we recognized that it is
reasonable not to refer some patients whose GFR
is below this threshold if the GFR is stable and the
diagnosis is relatively clear, or if very advanced
age or the presence of comorbidity indicates a
short life expectancy.We disagreed with the KDIGO
recommendations for nephrology referral in the
domain of AKI and the level of proteinuria for which
patients may need referral. AKI in the primary care
setting can often be effectively managed there with
treatment of the precipitating cause (such as
intercurrent illnesses and volume contraction),
temporary discontinuation of RAS blockade and
nonsteroidal anti-inﬂammatory medications, and
correction of obstruction. A nephrologist or internist
with an expertise in kidney disease should be sought
in patients with an abrupt sustained decrease
in eGFR. 20% (opinion-based threshold) after
excluding reversible causes, or if there are features
suggestive of a diagnosis other than prerenal azotemia
or acute tubular necrosis.
It should be recognized that the vast majority of
patients with stage 3 CKD do not progress to ESRD
but die mainly from cardiovascular causes.41 Primary
care intervention for cardiovascular risk reduction
should be strongly considered.
Regarding proteinuria, KDIGO recommends
referral to nephrology when ACR is$30 mg/mmol orPCR is $50 mg/mmol as these patients are at risk for
cardiovascular mortality and morbidity and RRT.
Although there are few data on the speciﬁc threshold
for proteinuria that will identify those who beneﬁt
from nephrology referral, the higher the proteinuria,
the greater the risk of ESRD.167,168 Immunosuppres-
sive medications are generally not indicated unless
proteinuria is . 1 g/d169 (ACR $ 60 mg/mmol or
PCR$ 100 mg/mmol) and kidney biopsy in North
America is generally not undertaken when kidney
function is stable and proteinuria is , 1 g/d.170 These
patients are treated with nonspeciﬁc therapy that can
be instituted by primary care. We recommend
referral to nephrology if there is persistent pro-
teinuria with protein excretion . 1 g/d
(ACR $ 60 mg/mmol or PCR $ 100 mg/mmol) as
at this level of proteinuria, renal biopsy may be
indicated and immunosuppressive medications may
need to be considered. In addition, we thought that a
nephrologist’s opinion may be beneﬁcial if patients
do not tolerate renal protective medications. Other
reasons for referral, in addition to those listed in the
guideline, are uncertainty about the diagnosis, sus-
pected polycystic kidney disease or hereditary
nephritis, inability to meet BP goals, severe electro-
lyte abnormalities, recurrent nephrolithiasis, unex-
plained or unexpected low GFR, or change in GFR,
especially in the nonelderly.
Referral for Planning for RRT5.1.2: We recommend timely referral for planning renal
replacement therapy (RRT) in people with progressive
CKD in whom the risk of kidney failure within 1 year
is 10-20% or highery, as determined by validated risk
prediction tools. (1B)
yThe aim is to avoid late referral, defined here as
referral to specialist services less than 1 year before
start of RRT.
Commentary
We add the caveat that the planning process in
these patients should include the discussion of con-
servative management without RRT. Further work is
needed on the appropriate threshold, in terms of level
of GFR or proteinuria or predicted risk for ESRD, for
appropriate initiation of planning for ESRD.
Routine Multidisciplinary Care for People With
Progressive CKD5.2.1: We suggest that people with progressive CKD should
be managed in a multidisciplinary care setting. (2B)Commentary
This recommendation is resource intensive and
evidence of cost-effectiveness is lacking. We agreed
(opinion) that patients with progressive CKD whoAm J Kidney Dis. 2015;65(2):177-205
CSN Commentaryare at high risk of ESRD and have eGFRs , 30 mL/
min/1.73 m2, those with rapid progression, or those
with complex comorbidity may beneﬁt from a
multidisciplinary approach. Evidence supporting
this recommendation is observational with potential
for bias.
Characteristics of the Multidisciplinary Team5.2.2: The multidisciplinary team should include or have
access to dietary counseling, education and coun-
seling about different RRT modalities, transplant
options, vascular access surgery, and ethical, psy-
chological, and social care. (Not Graded)Implications Within Canadian Health Care
As with recommendations 5.1.2 and 5.2.1, we
recognized that the increased resources needed for
the approach recommended in statement 5.2.2 might
not be available in all programs and that policy
makers have also to consider the opportunity costs.
Some patients in rural areas will not have local ac-
cess to all the recommended disciplines listed in
these KDIGO recommendations. Imaginative and
ﬂexible models of care are needed to make best use
of local resources and to support travel to tertiary
centers when needed.
Timing the Initiation of RRT5.3.1: We suggest that dialysis be initiated when one or
more of the following are present: symptoms or signs
attributable to kidney failure (serositis, acid base
or electrolyte abnormalities, pruritus); inability to
control volume status or blood pressure; a progres-
sive deterioration in nutritional status refractory to
dietary intervention; or cognitive impairment. This
often but not invariably occurs in the GFR range
between 5 and 10 ml/min/1.73 m2. (2B)
5.3.2: Living donor preemptive renal transplantation in
adults should be considered when the GFR is,20 ml/
min/1.73 m2, and there is evidence of progressive
and irreversible CKD over the preceding 6-12 months.
(Not Graded)Commentary
See the CSN guideline on timing of the initiation of
RRT.171
Conservative Management5.4.1: Conservative management should be an option in
people who choose not to pursue RRT and this should
be supported by a comprehensive management pro-
gram. (Not Graded)Commentary
Our CSN commentary committee concurred with
the recommendations, but acknowledged the many
barriers to this becoming reality, including limited
resources, lack of funding, and lack of a coordinatedAm J Kidney Dis. 2015;65(2):177-205approach to providing conservative renal therapy and
palliative care to this patient group, as well as the
possibility that general palliative support services
may be available and have all the necessary expertise.
As well, we acknowledge that some providers may
be unwilling or unable to address issues required
for patients to experience optimal end-of-life care,
without RRT.
All CKD Programs and Providers to Delivery of
Advanced Care Planning5.4.2: All CKD programs and care providers should be able
to deliver advance care planning for people with
a recognized need for end-of-life care, including those
people undergoing conservative kidney care.
(Not Graded)Commentary
In addition, we recommend that all efforts should
be made to involve primary care providers in advance
planning and end-of-life care.
Coordinated End-of-Life Care5.4.3: Coordinated end-of-life care should be available to
people and families through either primary care
or specialist care as local circumstances dictate.
(Not Graded)
5.4.4: The comprehensive conservative management
program should include protocols for symptom and
pain management, psychological care, spiritual care,
and culturally sensitive care for the dying patient
and their family (whether at home, in a hospice or a
hospital setting), followed by the provision of culturally
appropriate bereavement support. (Not Graded)Commentary
We agreed with this recommendation in principle,
though protocols are not always necessary to provide
effective individualized care. However, we recognize
that there is observational evidence172 supporting
a comprehensive conservative renal management
program.
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